Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Commitment to operational efficiency and partnerships yield dividends for Teva

By Brian Buntz | November 9, 2023

TevaTeva’s strategy to boost its operational efficiency and tap strategic partnerships seems to be paying off. In its Q3 earnings report, Teva announced that global revenues were up to $3.9 billion, marking a 7% rise from the previous year’s third quarter. Factors fueling the growth include the robust performance of their specialty medications, Austedo and Ajovy, as well as a strong showing from their generics portfolio. However, despite these promising stats, investors appear to be cautious. Teva’s stock is down almost 8% so far this year, currently trading at $8.77.

For Austedo, Sven Dethlefs, the company’s head of North America commercial, noted that the company has seen growth for the extended-release version of the drug. In an earnings call, Dethlefs said the company has seen  “a significant number of new prescribers that have never prescribed Austedo before that now start prescribing Austedo XR.”  He added that the demand for the XR version of the drug puts the company on the right track in “making Austedo a continuous growth driver” for its business.

A rosy outlook for 2024

The company bolstered its outlook for 2024, forecasting its revenue to fall in the range of $15.1 to $15.5 billion. Factors behind the optimistic projection include an exclusive deal with Sanofi aimed at developing and commercializing new treatments. The company has also made progress with its “Pivot to Growth” strategy, which involves fortifying its commercial offerings with profitable drugs and biosimilars. Other pillars of the strategy include homing in on neuroscience and immunology, sustaining its established presence in the generics marketplace, and allocating capital to fuel these areas of growth.

Financial performance in context

With this “Pivot to Growth” strategy, Teva projects to surpass annual revenues of $2.5 billion from Austedo alone by 2027.

The graph below charts revenues alongside GAAP and non-GAAP earnings-per share (EPS). Teva financial performance

Given the current war in Israel, Teva has introduced a proactive strategy to ensure the safety and well-being of its workforce while maintaining its operational commitments.

Although Teva has projected growth into 2024, the company’s stock has fallen considerably since its peak in 2015, when it hit a high closing price of $67.06 on July 27, 2015. A number of factors are at play in the decline, including a considerable debt burden, legal entanglements, and challenges in converting earnings into free cash flow. As of mid-2021, Teva carried net debt of about $22.7 billion, and while the debt levels have been decreasing, they still constrain the company. In addition, Teva has faced a number of legal woes, ranging from patent disputes to the opioid litigation. In 2022, Teva joined Allergan (now a unit of AbbVie) in agreeing to pay $5B billion to settle opioid allegations.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
Thermo Fisher Scientific
Thermo Fisher to invest $2B on U.S. manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE